Analyst Ratings
Here’s a summary of recent ratings for Psykey and ResMed from MarketBeat.
| Sell | Hold | Buy | Strong Buy | Score | |
| Psykey | 0 | 0 | 0 | 0 | N/A |
| ResMed | 1 | 5 | 6 | 1 | 2.54 |
Analysts favor ResMed with a target price of $218.18, indicating a possible 9.09% drop. They see ResMed as a better investment than Psykey.
Insider & Institutional Ownership
55.0% of ResMed shares are owned by institutions, while 1.2% are held by insiders, suggesting a strong belief in ResMed’s long-term performance.
Valuation and Earnings
| Revenue | P/S Ratio | Net Income | EPS | P/E Ratio | |
| Psykey | N/A | N/A | N/A | ($0.41) | -0.05 |
| ResMed | $4.69B | 7.53 | $1.02B | $6.51 | 36.87 |
ResMed outperforms Psykey in revenue and earnings, but Psykey is more affordable based on earnings.
Profitability
| Net Margin | Return on Equity | Return on Assets | |
| Psykey | N/A | N/A | N/A |
| ResMed | 21.79% | 25.00% | 16.67% |
Summary
ResMed outshines Psykey across all evaluated metrics.
About Psykey
Psykey, Inc. specializes in developing ingredients for health products and psychedelic therapies. Founded in 2002 and based in Toronto, it was previously known as CeCors, Inc.
About ResMed
ResMed Inc. creates medical devices and software for healthcare markets. Founded in 1989, its headquarters are in San Diego, California.
Receive News & Ratings for Psykey Daily – Enter your email to get the latest news and ratings with MarketBeat.com’s FREE daily email newsletter.
`
